Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Vistusertib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR known ✓ | P42345 | 20/20 | 1.00 |
| ▸ | PIK3CA | P42336 | 2/20 | 1.00 |
| ▸ | PIK3CD | O00329 | 1/20 | 1.00 |
| ▸ | PIK3R1 | P27986 | 1/20 | 1.00 |
| ▸ | PIK3CB | P42338 | 1/20 | 1.00 |
| ▸ | PIK3CG | P48736 | 1/20 | 1.00 |
| ▸ | PFKP | Q01813 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | RPTOR | Q8N122 | 1/20 | 1.00 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 1.00 |
| ▸ | MLST8 | Q9BVC4 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vistusertib SCHEMBL20734874 | 1.00 | MTOR (1.00) | MTORPIK3CAPIK3CDPIK3R1PIK3CB | |
| Vistusertib SCHEMBL1214881 | 1.00 | MTOR (1.00) | MTORPIK3CAPIK3CDPIK3R1PIK3CB | |
| Vistusertib SCHEMBL22449928 | 1.00 | MTOR (1.00) | MTORPIK3CAPIK3CDPIK3R1PIK3CB | |
| Vistusertib SCHEMBL29350053 | 1.00 | MTOR (1.00) | MTORPIK3CAPIK3CDPIK3R1PIK3CB | |
| Vistusertib SCHEMBL29397309 | 1.00 | MTOR (1.00) | MTORPIK3CAPIK3CDPIK3R1PIK3CB | |
| Vistusertib SCHEMBL290672 | 1.00 | MTOR (1.00) | MTORPIK3CAPIK3CDPIK3R1PIK3CB | |
| SCHEMBL22449835 | 0.95 | MTOR (0.90) | MTORPIK3CAPIK3CDPIK3R1PIK3CB | |
| SCHEMBL10225658 | 0.94 | MTOR (0.89) | MTORPIK3CAPIK3CDPIK3R1PIK3CB | |
| SCHEMBL22858573 | 0.94 | MTOR (0.89) | MTORPIK3CAPIK3CDPIK3R1PIK3CB | |
| SCHEMBL22030452 | 0.94 | MTOR (0.89) | MTORPIK3CAPIK3CDPIK3R1PIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1646 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637720-B2 | Molecular subtyping of small cell lung cancer to predict therapeutic responses | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2026-05-26 | — | — | US | claimed |
| EP-4363043-B1 | COMPOSITIONS FOR USE IN METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS | NOVOCURE GMBH (CH) | 2026-04-22 | — | — | EP | claimed |
| US-20260097038-A1 | COMPOSITIONS OF ADAGRASIB AND mTOR INHIBITORS AND METHODS OF TREATMENT THEREWITH | Mirati Therapeutics, Inc. (US) | 2026-04-09 | — | — | US | claimed |
| US-20260097028-A1 | Methods of Treating Myeloproliferative Neoplasms | KARTOS THERAPEUTICS INC (US) | 2026-04-09 | — | — | US | claimed |
| US-12594421-B2 | Compositions and methods for increasing cancer cell sensitivity to alternating electric fields | NOVOCURE GMBH (CH) | 2026-04-07 | — | — | US | claimed |
| US-20260053943-A1 | NANOCOMPOSITION COMPRISING ANTIBODY-DRUG CONJUGATE AND USE THEREOF | FULGENT GENETICS INC (US) | 2026-02-26 | — | — | US | claimed |
| EP-4698175-A1 | LYSINE ACETYLTRANSFERASE 6A (KAT6A) INHIBITOR, COMBINATIONS AND USES THEREOF | Insilico Medicine IP Limited (HK) | 2026-02-25 | — | — | EP | claimed |
| US-20260041692-A1 | COMPOSITION FOR PREVENTION OR TREATMENT OF INTRACTABLE EPILEPSY COMPRISING mTOR INHIBITOR | SOVARGEN CO LTD (KR) | 2026-02-12 | — | — | US | claimed |
| US-12527795-B2 | Compositions of adagrasib and mTOR inhibitors and methods of treatment therewith | Mirati Therapeutics, Inc. (US) | 2026-01-20 | — | — | US | claimed |
| EP-3639854-B1 | MTOR-INHIBITOR-CONTAINING MEDICINE FOR TREATING OR PREVENTING FUCHS' ENDOTHELIAL CORNEAL DYSTROPHY | THE DOSHISHA (JP) | 2026-01-07 | — | — | EP | claimed |
| EP-3980078-A1 | COMBINATION THERAPY COMPRISING AN ANTI-CD25 ANTIBODY DRUG CONJUGATE AND A FURTHER AGENT | ADC Therapeutics SA (CH) | 2022-04-13 | — | — | EP | claimed |
| EP-3980037-A2 | CARDIOMYOCYTES AND COMPOSITIONS AND METHODS FOR PRODUCING THE SAME | President and Fellows of Harvard College (US) | 2022-04-13 | — | — | EP | claimed |
| CN-114302746-A | Combination therapy comprising an anti-CD 25 antibody drug conjugate and another agent | ADC治疗有限公司 | 2022-04-08 | — | — | CN | claimed |
| US-20220096818-A1 | Compositions And Methods For Increasing Cancer Cell Sensitivity To Alternating Electric Fields | BIOPHARMA CREDIT PLC (GB) | 2022-03-31 | — | — | US | claimed |
| EP-3474841-B1 | AR+ BREAST CANCER TREATMENT METHODS | ELLIPSES PHARMA LTD (GB) | 2022-03-16 | — | — | EP | claimed |
| US-20220040182-A1 | COMBINATION THERAPIES | Mirati Therapeutics, Inc. | 2022-02-10 | — | — | US | claimed |
| WO-2022029334-A1 | COMBINATION THERAPIES FOR TREATING CORONAVIRUS INFECTION | GBIOTECH S.À.R.L. (CH) | 2022-02-10 | — | — | WO | claimed |
| WO-2022029628-A1 | COMPOSITIONS AND METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS | NOVOCURE GMBH (CH) | 2022-02-10 | — | — | WO | claimed |
| WO-2022017524-A1 | PYRIDONE COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 深圳晶泰科技有限公司 | 2022-01-27 | — | — | WO | claimed |
| CN-112168830-B | Medicine composition containing mTOR inhibitor and application thereof | 苏州亚盛药业有限公司 | 2022-01-25 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12527795-B2 | Compositions of adagrasib and mTOR inhibitors and methods of treatment therewith | KRAS, NRAS, HRAS | MTOR 19/4885PIK3CA 6/4885PIK3CD 21/4885 |
| US-20260097028-A1 | Methods of Treating Myeloproliferative Neoplasms | JAK2, TP53, CDKN1A | MTOR 15/4885PIK3CA 52/4885PIK3CD 202/4885 |
| US-20260041692-A1 | COMPOSITION FOR PREVENTION OR TREATMENT OF INTRACTABLE EPILEPSY COMPRISING mTOR INHIBITOR | MTOR, MAPKAP1, RPTOR | MTOR 1/4885PIK3CA 347/4885PIK3CD 100/4885 |
| US-12594421-B2 | Compositions and methods for increasing cancer cell sensitivity to alternating electric fields | PTK2, GSK3B, MTOR | MTOR 3/4885PIK3CA 13/4885PIK3CD 18/4885 |
| US-20260097038-A1 | COMPOSITIONS OF ADAGRASIB AND mTOR INHIBITORS AND METHODS OF TREATMENT THEREWITH | KRAS, NRAS, BRAF | MTOR 9/4885PIK3CA 15/4885PIK3CD 21/4885 |
| US-20220040182-A1 | COMBINATION THERAPIES | KRAS, NRAS, HRAS | MTOR 6/4885PIK3CA 9/4885PIK3CD 57/4885 |
| US-20260053943-A1 | NANOCOMPOSITION COMPRISING ANTIBODY-DRUG CONJUGATE AND USE THEREOF | CD47, PBK, CD4 | MTOR 2965/4885PIK3CA 1959/4885PIK3CD 1563/4885 |
| US-12637720-B2 | Molecular subtyping of small cell lung cancer to predict therapeutic responses | POU2F1, POU2F2, PARP2 | MTOR 995/4885PIK3CA 482/4885PIK3CD 282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.